APPROVED DRUG PRODUCTS
With Therapeutic Equivalence Evaluations

The "Orange Book"

FDA data supplied by DrugPatentWatch.com

The University of Michigan Pharmacy Library

CUMULATIVE SUPPLEMENT 1
AUG '82 - SEP '82

REFERENCE
DOES NOT CIRCULATE

PHARMACY
Rpp 3ed. Suppl. 1



APPROVED PRESCRIPTION DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

3RD EDITION

SERIAL
REFERENCE

JAN 24 1983
PHARMACY LIBRARY
THE UNIVERSITY OF MICHIGAN

UNIVERSITY OF MICHIGAN LIBRARIES
DEC 2 1982
DEPOSITED BY THE UNITED STATES OF AMERICA

HE20.4210:982/supp.1
499-K-3

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
NATIONAL CENTER FOR DRUGS AND BIOLOGICS

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

Digitized by Google

Original from
UNIVERSITY OF MICHIGAN

FOOD AND DRUG ADMINISTRATION
APPROVED PRESCRIPTION DRUG PRODUCTS
WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS
CUMULATIVE SUPPLEMENT

I. PREFACE

This cumulative supplement is one of a series of monthly updates to the Approved Prescription Drug Products with Therapeutic Equivalence Evaluations, 3rd Edition, (the List) to cover interim revisions to the annual publication of the List in its entirety. The List is comprised of several parts and some by their nature are identified by the term "list". The cumulative supplements routinely provide updates to two of these lists: The Drug Product List and the Addendum: DESI Pending List.

The List cannot be used effectively without the current cumulative supplement. Users may wish to place an asterisk (*) in the List to the left of the ingredient(s) in the Drug Product List and the product name in the Addendum to indicate that changes to that entry appear in the cumulative supplement. It is also suggested that earlier cumulative supplements be discarded to avoid possible confusion. In this way, only the List and current cumulative supplement need be referenced.

A. DRUG PRODUCT LIST

The Drug Product List cumulative supplements include the changes made since August 1, 1982. Each subsequent cumulative supplement replaces the previous month's cumulative supplement.

Information in this cumulative supplement follows the format of the Drug Product List. The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Context information on drug products is provided in each cumulative supplement for completeness to assist in locating the proper place in the Drug Product List for the revision. (Strength(s) which already exist in the publication will not be repeated for context.) A page number in parentheses referring to the Drug Product List is located to the right of the ingredient(s).

Additions to the Drug Product List are indicated by new information in the cumulative supplement. Additions new to the current cumulative supplement are indicated by the symbol >ADD> to the left of the line on which new information exists. The >ADD> symbol is dropped in subsequent cumulative supplements for that item.

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

Deletions from the Drug Product List are indicated by overstruck print in the cumulative supplement. Deletions new to the current cumulative supplement are indicated by the symbol >DLT< (DELETE) to the left of the line containing the overstruck print. The >DLT< symbol is dropped in subsequent cumulative supplements for that item.

A newly approved product is identified by the lozenge (⌘) to the right of its strength. This identifier remains throughout all cumulative supplements for this edition.

B. ADDENDUM: DESI Pending List

Information in this cumulative supplement follows the format of the Addendum. Additions and deletions are indicated in the same manner as in the cumulative supplement to the Drug Product List. A change in Current Status of a DESI product is also indicated by an addition and a deletion.

II. SPECIAL NOTES

A. INDICES AND ABBREVIATIONS:

STANDARD TERMS:

Added Route of Administration: INTRAPERITONEAL

B. REPORT OF COUNTS FOR THE DRUG PRODUCT LIST

Beginning with this cumulative supplement, categories of counts derived from product information in the Drug Product List and from this cumulative supplement are presented. The format of this report and the categories reported may change from time to time.

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

III. REPORT OF COUNTS FOR THE DRUG PRODUCT LIST

DESCRIPTION OF REPORT

The following report provides summary counts derived from product information in the Drug Product List and the current cumulative supplement. The counts appear in two sections. Section A. refers to the products in the List and Section B. to products in the current cumulative supplement. A new column of data will appear in Section A. each three-month period following July '82. Section A. therefore will provide baseline and quarterly data while Section B. provides monthly activity.

USE OF REPORT

From the data presented, users should be able to observe such things as (1) newly approved, DESI effective and remarketed drug products which are added to the List; (2) products that are being removed from the List as the result of withdrawal of approval, changes from prescription to over-the-counter status and discontinued marketing of products; and, (3) trends in products as either multisource or single source.

Drug Product Definition

For this report, a drug product is the representation in the Drug Product List of an active moiety or its derivatives (ingredient), either as a single entity or as a combination product, provided in a specific dosage form and strength for a given route of administration marketed by a firm under a particular generic or trade name.

Drug Product Count

This report provides counts in several categories from the list composed of domestically marketed drug products approved for both safety and effectiveness under sections 505 and 507 of the Federal Food, Drug, and Cosmetic Act. Counts of products still pending in the DESI review are not provided. Excluded also are those approved drug products marketed by distributors; those marketed solely abroad; and products now regarded as medical devices, biologics or foods. Also not included in the counts are those duplicate products of a given applicant whose only distinguishing characteristics are items such as package size, inactive ingredient(s), color and alternate manufacturing sites. These various counts are excluded because the Drug Product List itself excludes products from these categories.

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

REPORT OF COUNTS FOR THE DRUG PRODUCT LIST

A. COUNTS CUMULATIVE BY QUARTERS

CATEGORIES COUNTED	JULY '82
DRUG PRODUCTS LISTED	6303
SINGLE SOURCE	1885 (30%)
MULTISOURCE(1)	4418 (70%)
THERAPEUTICALLY EQUIVALENT	3456 (54.8%)
NOT THERAPEUTICALLY EQUIVALENT	954 (15.1%)
EXCEPTIONS(2)	8 (0.1%)
NUMBER OF APPLICANTS	303

B. ACTIVITY FOR SUPPLEMENT NUMBER 1 AND CUMULATIVE SINCE JULY '82

	AUG-SEPT '82		CUMULATIVE	
DRUG PRODUCTS ADDED:	85		85	
NEWLY APPROVED		85		85
DESI EFFECTIVE		0		0
REMARKETED		0		0
DRUG PRODUCTS REMOVED:	18		18	
WITHDRAWN APPROVAL		0		0
RX TO OTC SWITCH		2		2
DISCONTINUED MARKETING		16		16
NET GAIN IN DRUG PRODUCTS	67		67	
NEW SINGLE SOURCE PRODUCTS	26		26	
NEW MULTISOURCE DRUG PRODUCTS	59		59	

(1) THERAPEUTIC EQUIVALENCE EVALUATIONS PROVIDED ONLY FOR MULTISOURCE PRODUCTS (i.e., AVAILABLE FROM MORE THAN ONE APPLICANT)

(2) AMINO ACID-CONTAINING PRODUCTS OF VARYING COMPOSITION (SEE PAGE 2-8 OF THE LIST)

> ADD > ACETAMINOPHEN; PENTAZOCINE HYDROCHLORIDE (PAGE 3-2)

> ADD > TABLET; ORAL
> ADD > TALACEN
> ADD > STERLING DRUG 650MG;EQ 25MG BASE*

AMINO ACIDS (PAGE 3-6)

INJECTABLE; INJECTION
> ADD > NOVAMINE 8.5%
> ADD > CUTTER LABORATORIES 8.5%*
> ADD > NOVAMINE 11.4%
> ADD > CUTTER LABORATORIES 11.4%*

AMPHETAMINE ADIPATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE ADIPATE; DEXTROAMPHETAMINE SULFATE (PAGE 3-11)

CAPSULE; ORAL
DELCOBESE
> DLT > /DELCO CHEMICAL/ /1.25MG;1.25MG;1.25MG;1.25MG/
> DLT > /2.5MG;2.5MG;2.5MG;2.5MG/
> DLT > /3.75MG;3.75MG;3.75MG;3.75MG/
> DLT > /5MG;5MG;5MG;5MG/
> ADD > LEMMON 1.25MG;1.25MG;1.25MG;1.25MG
> ADD > 2.5MG;2.5MG;2.5MG;2.5MG
> ADD > 3.75MG;3.75MG;3.75MG;3.75MG
> ADD > 5MG;5MG;5MG;5MG

TABLET; ORAL
DELCOBESE
> DLT > /DELCO CHEMICAL/ /1.25MG;1.25MG;1.25MG;1.25MG/
> DLT > /2.5MG;2.5MG;2.5MG;2.5MG/
> DLT > /3.75MG;3.75MG;3.75MG;3.75MG/
> DLT > /5MG;5MG;5MG;5MG/
> ADD > LEMMON 1.25MG;1.25MG;1.25MG;1.25MG
> ADD > 2.5MG; 2.5MG;2.5MG;2.5MG
> ADD > 3.75MG;3.75MG;3.75MG;3.75MG
> ADD > 5MG;5MG;5MG;5MG

ASPIRIN; CAFFEINE; PHENACETIN; PROPOXYPHENE HYDROCHLORIDE (PAGE 3-15)

CAPSULE; ORAL
> DLT > /PROPOXYPHENE HCL COMPOUND 65/
> DLT >/AA/ /ROXANE LABORATORIES//227MG;32.4MG;162MG;65MG/

Digitized by Google

> ADD > AZLOCILLIN SODIUM (PAGE 3-17)

> ADD > INJECTABLE; INJECTION
> ADD > AZLIN
> ADD > MILES PHARMS/MILES EQ 2GM BASE/VIAL*
> ADD > EQ 3GM BASE/VIAL*
> ADD > EQ 4GM BASE/VIAL*

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE (PAGE 3-18)

OINTMENT; OPHTHALMIC
BACITRACIN-NEOMYCIN-POLYMYXIN
> ADD > AT BYK-GULDEN 400 UNITS/GM;EQ 3.5MG BASE/GM;
> ADD > AT 10,000 UNITS/GM
> ADD > BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE
> ADD > AT PHARMAFAIR 400 UNITS/GM;EQ 3.5MG BASE/GM;
> ADD > AT 10,000 UNITS/GM*

BETAMETHASONE VALERATE (PAGE 3-20)

> DLT > /AEROSOL; TOPICAL/
> DLT > /VALISONE/
> DLT > /SCHERING/ /0.1%/

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE (PAGE 3-25)

> DLT > /INJECTABLES; INJECTION/
> ADD > SOLUTION; INTRAPERITONEAL
DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER
> ADD > AT TRAVENOL LABS 25.7MG/100ML;1.5GM/100ML;
> ADD > AT 5.0SMG/100ML;558MG/100ML;448MG/100ML
DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER
> ADD > AT TRAVENOL LABS 25.7MG/100ML;2.5GM/100ML;
> ADD > AT 5.0SMG/100ML;558MG/100ML;448MG/100ML
DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER
> ADD > AT TRAVENOL LABS 25.7MG/100ML;4.25GM/100ML;
> ADD > AT 5.0SMG/100ML;558MG/100ML;448MG/100ML
> ADD > INPERSOL-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER
> ADD > AT ABBOTT LABORATORIES 25.7MG/100ML;1.5GM/100ML;
> ADD > AT 5.0SMG/100ML;558MG/100ML;448MG/100ML*
> ADD > INPERSOL-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER
> ADD > AT ABBOTT LABORATORIES 25.7MG/100ML;2.5GM/100ML;
> ADD > AT 5.0SMG/100ML;558MG/100ML;448MG/100ML*
> ADD > INPERSOL-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER
> ADD > AT ABBOTT LABORATORIES 25.7MG/100ML;4.25GM/100ML;
> ADD > AT 5.0SMG/100ML;558MG/100ML;448MG/100ML*

UNIVERSITY OF MICHIGAN

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

CALCIUM GLUCEPTATE (PAGE 3-26)

INJECTABLE; INJECTION
CALCIUM GLUCEPTATE
>ADD > AP INTL MEDICATION SYS EQ 90MG CALCIUM/5ML*

CHLORAMPHENICOL SODIUM SUCCINATE (PAGE 3-31)

INJECTABLE; INJECTION
CHLORAMPHENICOL SODIUM SUCCINATE
>ADD > AP LYPHO-MED EQ 1GM BASE/VIAL*

CHLOROTHIAZIDE (PAGE 3-33)

TABLET; ORAL
CHLOROTHIAZIDE
>ADD > AB BOLAR PHARMACEUTICAL 500MG*

CHLORPHENIRAMINE MALEATE (PAGE 3-34)

SYRUP; ORAL
>DLT > /HISTREY/
>DLT >/AA/ /BONNAN PHARMS/ /2MG/5ML/

CHLORPROMAZINE HYDROCHLORIDE (PAGE 3-35)

TABLET; ORAL
CHLORPROMAZINE HCL
>ADD > BP VANGARD LABS/MWM 10MG*
>ADD > BP WEST-WARD 10MG*
>ADD > BP 25MG*
>ADD > BP 50MG*
>ADD > BP 100MG*
>ADD > BP 200MG*

CHLORZOXAZONE (PAGE 3-37)

TABLET; ORAL
CHLORZOXAZONE
>ADD > AA CHELSEA LABORATORIES 250MG*

CYCLOPHOSPHAMIDE (PAGE 3-44)

INJECTABLE; INJECTION
CYTOXAN
>ADD > MEAD JOHNSON/B-M 1GM/VIAL*
>ADD > 2GM/VIAL*

CYPROHEPTADINE HYDROCHLORIDE (PAGE 3-44)

TABLET; ORAL
CYPROHEPTADINE HCL
>DLT >/AA/ /FREMD PHARM LABS/ /4MG/
>ADD > AA LEMMON 4MG

DEXAMETHASONE (PAGE 3-47)

TABLET; ORAL
DEXAMETHASONE
>ADD > BP ROXANE LABORATORIES 2MG*

DEXAMETHASONE SODIUM PHOSPHATE (PAGE 3-48)

INJECTABLE; INJECTION
>ADD > DEXAMETHASONE
>ADD > AP ELKINS-SINN/AHROBINS EQ 4MG PHOSPHATE/ML
>ADD > AP EQ 10MG PHOSPHATE/ML*
DEXAMETHASONE SODIUM PHOSPHATE
>DLT >/AP/ /ELKINS-SINN/AHROBINS/EQ 4MG PHOSPHATE/ML/

>DLT > /DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE/(PAGE 3-49)

>DLT > /TABLET; ORAL/
>DLT > /DISOPHROL/
>DLT > /SCHERING/ /2MG;60MG/

>DLT > /TABLET, CONTROLLED RELEASE; ORAL/
>DLT > /DRIXORAL/
>DLT > /SCHERING/ /6MG;120MG/

DIATRIZOATE MEGLUMINE (PAGE 3-54)

INJECTABLE; INJECTION
>ADD > ANGIOVIST 282
>ADD > AP BERLEX/SCHERING AG 60%*
>ADD > UROVIST MEGLUMINE DIU/CT
>ADD > AP BERLEX/SCHERING AG 30%*

SOLUTION; URETHRAL
>ADD > UROVIST CYSTO
>ADD > AT BERLEX/SCHERING AG 30%*
>ADD > UROVIST CYSTO PEDIATRIC
>ADD > AT BERLEX/SCHERING AG 30%*

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM (PAGE 3-54)

INJECTABLE; INJECTION
> ADD > ANGIOVIST 292
> ADD > AP BERLEX/SCHERING AG 52%;82%
> ADD > ANGIOVIST 370
> ADD > AP BERLEX/SCHERING AG 66%;102%

SOLUTION; ORAL, RECTAL
> ADD > GASTROVIST
> ADD > AA BERLEX/SCHERING AG 66%;102%

DIATRIZOATE SODIUM (PAGE 3-54)

INJECTABLE; INJECTION
> ADD > UROVIST SODIUM 300
> ADD > AP BERLEX/SCHERING AG 50%

DIMENHYDRINATE (PAGE 3-57)

> DLT > /SUPPOSITORY; RECTAL/
> DLT > /DRAMAMINE/
> DLT > /SEARLE PHARMS/ /100MG/

DIPHENHYDRAMINE HYDROCHLORIDE (PAGE 3-58)

CAPSULE; ORAL
DIPHENHYDRAMINE HCL
> DLT > /PREMO PHARM LABS/ /25MG/
> DLT > /50MG/

DOPAMINE HYDROCHLORIDE (PAGE 3-60)

INJECTABLE; INJECTION
DOPAMINE HCL
> ADD > AP ABBOTT LABORATORIES 80MG/ML*

DOXYCYCLINE HYCLATE (PAGE 3-61)

TABLET; ORAL
> ADD > DOXYCYCLINE HYCLATE
> ADD > AB BARR LABORATORIES EQ 100MG BASE*

EPINEPHRINE; ETIDOCAINE HYDROCHLORIDE (PAGE 3-62)

INJECTABLE; INJECTION
> DLT > /DURANEST W/ EPINEPHRINE/
> ADD > DURANEST

Digitized by Google

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE (PAGE 3-63)

INJECTABLE; INJECTION
XYLOCAINE W/ EPINEPHRINE
> ADD > ASTRA PHARM PRODS 0.005MG/ML;0.5%*

ERGOLOID MESYLATES (PAGE 3-63)

TABLET; ORAL
ERGOLOID MESYLATES
> ADD > AB DANBURY PHARMACAL 1MG*

TABLET; SUBLINGUAL
> ADD > M.E.A.
> ADD > AA VANGARD LABS/MWM 0.5MG*
> ADD > AA 1MG*

> DLT > /ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE; FERROUS FUMARATE/
(PAGE 3-69)

> DLT > /TABLET; ORAL-28/
> DLT > /DEMULEN-FE-28/
> DLT > /SEARLE/SEARLE PHARMS/0.05MG;1MG;75MG/

> ADD > ETOMIDATE (PAGE 3-71)

> ADD > INJECTABLE; INJECTION
> ADD > AMIDATE
> ADD > ABBOTT LABORATORIES 2MG/ML*

FENFLURAMINE HYDROCHLORIDE (PAGE 3-71)

> ADD > TABLET, CONTROLLED RELEASE; ORAL
> ADD > PONDIMIN
> ADD > AH ROBINS 60MG*

GENTAMICIN SULFATE (PAGE 3-76)

INJECTABLE; INJECTION
> ADD > ISOTONIC GENTAMICIN SULFATE IN PLASTIC CONTAINER
> ADD > TRAVENOL LABS EQ 0.8MG BASE/ML*
> ADD > EQ 80MG BASE/100ML*

> ADD > GONADORELIN HYDROCHLORIDE (PAGE 3-77)

> ADD > INJECTABLE; INJECTION
> ADD > FACTREL
> ADD > AYERST LABS/AMHO EQ 0.1MG BASE/VIAL*
> ADD > EQ 0.5MG BASE/VIAL*

Original from UNIVERSITY OF MICHIGAN

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE (PAGE 3-77)

SOLUTION/DROPS; OPHTHALMIC
NEOMYCIN SULFATE AND POLYMYXIN B SULFATE GRAMICIDIN
> ADD > AT PHARMAFAIR 0.025MG/ML;EQ 1.75MG BASE/ML;
> ADD > AT 5,000 UNITS/ML*
> ADD > 0.025MG/ML;EQ 1.75MG BASE/ML;
> ADD > 10,000 UNITS/ML*

> ADD > GUANABENZ ACETATE (PAGE 3-78)

> ADD > TABLET; ORAL
> ADD > WYTENSIN
> ADD > WYETH LABS/AMHO EQ 4MG BASE*
> ADD > EQ 8MG BASE*

HYALURONIDASE (PAGE 3-82)

INJECTABLE; INJECTION
> DLT > /ALTHASE/
> DLT >/AB/ /SEARLE PHARMS/ /150 UNITS/VIAL/
WYDASE
> DLT >/AB/ /WYETH LABS/AMHO/ /150 UNITS/VIAL/
> ADD > WYETH LABS/AMHO 150 UNITS/VIAL

HYDRALAZINE HYDROCHLORIDE (PAGE 3-82)

TABLET; ORAL
HYDRALAZINE HCL
> DLT >/AA/ /PREMO PHARM LABS/ /25MG/
> DLT >/AA/ /50MG/
> ADD > AA LEMMON 50MG

HYDROCORTISONE (PAGE 3-85)

LOTION; TOPICAL
NUTRACORT
> DLT >/AT/ /OWEN LABS/ALCON LABS/0.5%/
> DLT >/AT/ /1%/
> ADD > AT OWEN LABS/DERM PRODS 0.5%
> ADD > AT 1%
> ADD > 2.5%*

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE (PAGE 3-88)

SOLUTION; OTIC
> ADD > NEOMYCIN SULFATE-POLYMYXIN B SULFATE-HYDROCORTISONE "
> ADD > AT PHARMAFAIR 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML*

HYDROXYZINE PAMOATE (PAGE 3-91)

CAPSULE; ORAL
HY-PAM
> DLT >/AB/ /PREMO PHARM LABS/ /EQ 25MG HCL/
> DLT >/AB/ /EQ 50MG HCL/
> ADD > AB LEMMON EQ 25MG HCL
> ADD > AB EQ 50MG HCL
HYDROXYZINE PAMOATE
> ADD > AB DANBURY PHARMACAL EQ 50MG HCL*
> ADD > AB EQ 100MG HCL*

IMIPRAMINE HYDROCHLORIDE (PAGE 3-92)

TABLET; ORAL
IMIPRAMINE HCL
> DLT >/AB/ /PREMO PHARM LABS/ /10MG/
> DLT >/AB/ /25MG/
> DLT >/AB/ /50MG/
> ADD > AB LEMMON 10MG
> ADD > AB 25MG
> ADD > AB 50MG

IPODATE SODIUM (PAGE 3-95)

CAPSULE; ORAL
> ADD > BILIVIST
> ADD > AA BERLEX/SCHERING AG 500MG*
ORAGRAFIN SODIUM
> ADD > AA ER SQUIBB AND SONS 500MG

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE (PAGE 3-103)

SOLUTION; IRRIGATION
PHYSIOSOL IN PLASTIC CONTAINER
> DLT > /ABBOTT LABORATORIES//14MG/100ML;37MG/100ML;222MG/100ML;/
> DLT > /526MG/100ML;502MG/100ML/
> ADD > ABBOTT LABORATORIES 30MG/100ML;37MG/100ML;222MG/100ML;
> ADD > 526MG/100ML;502MG/100ML

> ADD > MALATHION (PAGE 3-104)

> ADD > LOTION; TOPICAL
> ADD > PRIODERM
> ADD > PURDUE FREDERICK 0.5%*

METHADONE HYDROCHLORIDE (PAGE 3-110)

SOLUTION; ORAL
METHADONE HCL
> ADD > ROXANE LABORATORIES 10MG/5ML*

METHANTHELINE BROMIDE (PAGE 3-111)

>DLT > /INJECTABLE; INJECTION/
>DLT > /BANTHINE/
>DLT > /SEARLE/SEARLE PHARMS/50MG/VIAL/

METHYCLOTHIAZIDE (PAGE 3-114)

TABLET; ORAL
METHYCLOTHIAZIDE
>ADD > AB MYLAN PHARMS 2.5MG*
>ADD > AB 5MG*

METRONIDAZOLE (PAGE 3-117)

INJECTABLE; INJECTION
>ADD > METRO I.V.
>ADD > AP AM HCGAW/AM HOSP 500MG/100ML*

TABLET; ORAL
METRONIDAZOLE
/AB/ /LEMMON/ /250MG/
>ADD > METRYL
>ADD > AB LEMMON 250MG

MINOCYCLINE HYDROCHLORIDE (PAGE 3-118)

>ADD > TABLET; ORAL
>ADD > MINOCIN
>ADD > LEDERLE LABS/AM CYAN EQ 50MG BASE*
>ADD > EQ 100MG BASE*

NYSTATIN (PAGE 3-123)

OINTMENT; TOPICAL
NYSTATIN
>ADD > AT BYK-GULDEN 100,000 UNITS/GM*

OXYTETRACYCLINE HYDROCHLORIDE (PAGE 3-126)

CAPSULE; ORAL
OXYTETRACYCLINE HCL
>DLT >/AB/ /LEDERLE LABS/AM CYAN/EQ 250MG BASE/

PHENDIMETRAZINE TARTRATE (PAGE 3-132)

CAPSULE; ORAL
PHENDIMETRAZINE TARTRATE
>DLT >/AA/ /CORD LABORATORIES/ /35MG/
>ADD > AA REID-PROVIDENT LABS 35MG
>ADD > X-TROZINE
>ADD > AA REXAR PHARMACAL 35MG*

PHENDIMETRAZINE TARTRATE (PAGE 3-132)

CAPSULE, CONTROLLED RELEASE; ORAL
>ADD > X-TROZINE L.A.
>ADD > BC REXAR PHARMACAL 105MG*

PHENTERMINE HYDROCHLORIDE (PAGE 3-133)

TABLET; ORAL
PHENTERMINE HCL
>DLT >/AA/ /CORD LABORATORIES/ /8MG/
>ADD > TORA
>ADD > AA REID-PROVIDENT LABS 8MG

>ADD > PINDOLOL (PAGE 3-135)

>ADD > TABLET; ORAL
>ADD > VISKEN
>ADD > SANDOZ PHARMS/SANDOZ 5MG*
>ADD > 10MG*
>ADD > 15MG*

PREDNISOLONE (PAGE 3-139)

TABLET; ORAL
PREDNISOLONE
>DLT > /BX/ /PUREPAC PHARMA/ /5MG/

PROBENECID (PAGE 3-142)

TABLET; ORAL
PROBENECID
>DLT >/AB/ /BEECHAM LABS/BEECHAM/500MG/

PROCHLORPERAZINE EDISYLATE (PAGE 3-144)

SYRUP: ORAL
COMPAZINE
>ADD > AA SK&F LABORATORIES EQ 5MG BASE/5ML
>ADD > PROCHLORPERAZINE EDISYLATE
>ADD > AA NATL PHARM MFG/BARRE EQ 5MG BASE/5ML*

PROMETHAZINE HYDROCHLORIDE (PAGE 3-145)

INJECTABLE; INJECTION
>DLT > /PHENGEN-50/
>DLT >/AB/ /CENTRAL PHARMS/ /50MG/ML/

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

Digitized by Google
UNIVERSITY OF MICHIGAN
Original from

PROPARACAINE HYDROCHLORIDE (PAGE 3-146)

SOLUTION/DROPS; OPHTHALMIC
PARACAINE
> ADD > AT PRO PHARMA/STERI-MED 0.5%

PROPOXYPHENE HYDROCHLORIDE (PAGE 3-147)

CAPSULE; ORAL
PROPOXYPHENE HCL
> DLT >/AA/ /FREMD PHARM LABS/ /65MG/
> ADD > AA LEMMON 65MG
> DLT >/AA/ /ROXANE LABORATORIES//65MG/

QUINIDINE GLUCONATE (PAGE 3-150)

TABLET, CONTROLLED RELEASE; ORAL
QUINIDINE GLUCONATE
> ADD > AB DANBURY PHARMACAL 324MG*

SULFABENZAMIDE; SULFACETAMIDE; SULFATHIAZOLE; UREA (PAGE 3-160)

CREAM; VAGINAL
SULMAC
> ADD > AT NMC LABORATORIES 3.7%;2.86%;3.42%;0.64%*

SULFINPYRAZONE (PAGE 3-162)

CAPSULE; ORAL
ANTURANE
> ADD > AB CIBA/CIBA-GEIGY 200MG
SULFINPYRAZONE
> ADD > AB BARR LABORATORIES 200MG*

TABLET; ORAL
SULFINPYRAZONE
> ADD > AB BARR LABORATORIES 100MG*

TECHNETIUM, TC-99M, MEDRONATE KIT (PAGE 3-164)

INJECTABLE; INJECTION
AMERSCAN
> ADD > AP AMERSHAM/RADIOCHEM N/A*

TECHNETIUM, TC-99M, SULFUR COLLOID (PAGE 3-165)

INJECTABLE; INJECTION
TECHNETIUM TC 99M SULFUR COLLOID
> DLT > /SYNCOR ANTL/ /5MCI/ML/

THEOPHYLLINE (PAGE 3-168)

SYRUP; ORAL
> DLT > /SLO-PHYLLIN-80/
> DLT >/AA/ /DOONER LABORATORIES//80MG/15ML/
> ADD > SLO-PHYLLIN
> ADD > AA WILLIAM H RORER 80MG/15ML

TABLET; ORAL
SLO-PHYLLIN
> DLT > /80/ /DOONER LABORATORIES//100MG/
> DLT > /80/ /200MG/
> ADD > BD WILLIAM H RORER 100MG
> ADD > BD 200MG

TABLET, CONTROLLED RELEASE; ORAL
> ADD > THEOCONTIN
> ADD > PURDUE FREDERICK 400MG*

TRIAMCINOLONE ACETONIDE (PAGE 3-173)

CREAM; TOPICAL
TRIAMCINOLONE ACETONIDE
> ADD > AT PHARMAFAIR 0.025%*
> ADD > AT 0.1%*
> ADD > AT 0.5%*

LOTION; TOPICAL
KENALOG
> ADD > AT ER SQUIBB AND SONS 0.025%
> ADD > AT 0.1%
> ADD > TRIAMCINOLONE ACETONIDE
> ADD > AT NATL PHARM MFG/BARRE 0.025%*
> ADD > AT 0.1%*

TRIFLUOPERAZINE HYDROCHLORIDE (PAGE 3-175)

CONCENTRATE; ORAL
> DLT > /TRIAZINE/
> ADD > TFP

TROPICAMIDE (PAGE 3-178)

SOLUTION/DROPS; OPHTHALMIC
MYDRIACYL
> ADD > AT ALCON LABORATORIES 1%
TROPICAMIDE
> ADD > AT PRO PHARMA/STERI-MED 1%*

WARFARIN SODIUM (PAGE 3-160)

TABLET; ORAL

		ATHROMBIN	
>_DLT_>	/BD/	/PURDUE FREDERICK/	/5MG/
>_DLT_>	/BD/		/10MG/
>_ADD_>	BX	PURDUE FREDERICK	5MG
>_ADD_>	BX		10MG
		COUMADIN	
>_DLT_>	/BD/	/ENDO LABS/DUPONT/	/2MG/
>_DLT_>	/BD/		/2.5MG/
>_DLT_>	/BD/		/5MG/
>_DLT_>	/BD/		/7.5MG/
>_DLT_>	/BD/		/10MG/
>_ADD_>	BX	ENDO LABS/DUPONT	2MG
>_ADD_>	BX		2.5MG
>_ADD_>	BX		5MG
>_ADD_>	BX		7.5MG
>_ADD_>	BX		10MG
		PANWARFIN	
>_DLT_>	/BD/	/ABBOTT LABORATORIES/	/2MG/
>_DLT_>	/BD/		/2.5MG/
>_DLT_>	/BD/		/5MG/
>_DLT_>	/BD/		/7.5MG/
>_DLT_>	/BD/		/10MG/
>_ADD_>	BX	ABBOTT LABORATORIES	2MG
>_ADD_>	BX		2.5MG
>_ADD_>	BX		5MG
>_ADD_>	BX		7.5MG
>_ADD_>	BX		10MG
>_ADD_>		WARFARIN SODIUM	
>_ADD_>	BX	BOLAR PHARMACEUTICAL	2MGM
>_ADD_>	BX		2.5MGM
>_ADD_>	BX		5MGM
>_ADD_>	BX		7.5MGM
>_ADD_>	BX		10MGM

Digitized by Google

Original from
UNIVERSITY OF MICHIGAN

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

ADDENDUM
DESI PENDING LIST
CUMULATIVE SUPPLEMENT NUMBER 1 / AUGUST '82 & SEPTEMBER '82

CURRENT STATUS - 'EXEMPT' (COURT ORDER)

>ADD<	DIPYRIDAMOLE	SUPERPHARM
>ADD<	DIPYRIDAMOLE	
>ADD<	ISOSORBIDE DINITRATE	INWOOD LABS/FOREST
>ADD<	ISOSORBIDE DINITRATE	
>ADD<	METHANDROSTENOLONE	PAR PHARMACEUTICAL
>ADD<	METHANDROSTENOLONE	
>ADD<	NITROGLYCERIN	VITARINE/WEST CHEM
>ADD<	NITROGLYCERIN	
>ADD<	NITROSTAT	PARKE-DAVIS/W-L
>ADD<	NITROGLYCERIN	

*U.S. GOVERNMENT PRINTING OFFICE:1982 381-927/103 1-3

SUBSCRIPTION FORM

APPROVED PRESCRIPTION DRUG PRODUCTS
WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS
3RD EDITION (1982)

MAIL TO:

DATE:

Superintendent of Documents
Government Printing Office
Washington, DC 20402
(202) 783-3238

PURCHASER:

SHIP TO:
(If different than purchaser)

CONTACT:

TELEPHONE (Include Area Code)

METHOD OF PAYMENT

[ ] Charge my GPO Account No. _____
[ ] Purchase Order Number _____
[ ] Check enclosed for $_____
(Make check payable to Superintendent of Documents)

AUTHORIZING SIGNATURE

DATE:

DESCRIPTION	QUANTITY	UNIT PRICE	TOTAL PRICE
The 3rd Edition will be published in October, 1982. Subscription includes the Approved Prescription Drug Products List and monthly Cumulative Supplements.			
DOMESTIC		@ $80.00	$
FOREIGN		@ $100.00	$
ENTER TOTAL			$

Digitized by Google
Original from UNIVERSITY OF MICHIGAN

Digitized by Google

Original from
UNIVERSITY OF MICHIGAN